FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Davidson David (Last) (First) (Middle) C/O BLUEBIRD BIO, INC. 60 BINNEY STREET (Street) CAMBRIDGE MA 02142						2. Issuer Name and Ticker or Trading Symbol bluebird bio, Inc. [BLUE] 3. Date of Earliest Transaction (Month/Day/Year) 11/01/2017 4. If Amendment, Date of Original Filed (Month/Day/Year)									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) Chief Medical Officer 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person				
(City)			(Zip)		-										Form filed by More than One Reporting Person				
		Tab	le I -	Non-Deriv	vative	e Sec	uriti	ies A	cquir	ed, D)isposed (of, or E	Benefi	cially	Owned	<u> </u>			
1. Title of Security (Instr. 3)				2. Transaction Date (Month/Day/		Executi		ate,	3. Transaction Code (Instr. 8)					Benefi		ies	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	irect direct l	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) or (D)	Price		Reporter Transact (Instr. 3				(Instr. 4)
Common Stock 1					17	17			M		4,000	Α	\$5.5	5004	19	,977	D		
Common Stock				11/01/20	2017				S ⁽¹⁾		1,628	D	\$144.	.436(2)	18	3,349	D		
Common Stock 11/01/					17	L7					1,272	D	\$145.3	3852 ⁽³⁾	17	,077	D		
Common Stock 11/01/2				17	.7			S ⁽¹⁾		1,100	D \$146.1		1364(4)	15,977		D			
		Т	able	II - Deriva (e.g., إ							sposed of				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exect if any	eemed ution Date, th/Day/Year)	4. Transa Code (8)			Expir	te Exer ation D th/Day/		7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		De Se (In	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownersh Form: Direct (D or Indire (I) (Instr.	vnership rm: rect (D) Indirect	Beneficial Ownership ct (Instr. 4)	
					Code	ode V		(D)	Date Exerc	cisable	Expiration Date	Title	Amo or Num of Shai	nber					
Stock Option (right to buy)	\$5.5004	11/01/2017			M			4,000	((5)	01/16/2023	Commo		000	\$0.00	83,151		D	

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2016.
- 2. The range of prices for the transaction reported on this line was \$144.00 to \$144.85. The average weighted price was \$144.4360. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 3. The range of prices for the transaction reported on this line was \$145.00 to \$145.75. The average weighted price was \$145.3852. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 4. The range of prices for the transaction reported on this line was \$146.00 to \$146.75. The average weighted price was \$146.1364. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 5. This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of May 1, 2013. The shares underlying these options vested as follows: 25% vested on May 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years.

Remarks:

/s/Jason F. Cole, Attorney-in-

11/03/2017

Fact

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.